WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H341556
CAS#: 34256-91-2
Description: Naranol hydrochloride is a biochemical.
Hodoodo Cat#: H341556
Name: Naranol hydrochloride
CAS#: 34256-91-2
Chemical Formula: C18H22ClNO2
Exact Mass: 319.13
Molecular Weight: 319.829
Elemental Analysis: C, 67.60; H, 6.93; Cl, 11.08; N, 4.38; O, 10.00
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Naranol hydrochloride; W 5494A; W-5494A; W5494A; W 5494 A.
IUPAC/Chemical Name: 7aH-Naphtho(1',2':5,6)pyrano(3,2-c)pyridin-7a-ol, 8,9,10,11,11a,12-hexahydro-8,10-dimethyl-, hydrochloride
InChi Key: IBSSDTOGUGCBDB-UHFFFAOYSA-N
InChi Code: InChI=1S/C18H21NO2.ClH/c1-12-10-19(2)11-14-9-16-15-6-4-3-5-13(15)7-8-17(16)21-18(12,14)20;/h3-8,12,14,20H,9-11H2,1-2H3;1H
SMILES Code: OC12C(CC3=C4C=CC=CC4=CC=C3O2)CN(C)CC1C.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 319.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Lin HW, Simonavice CA, Lu CR, Lin WL, Wu PL, Chou CY, Liao CH, Lane HY. Severe hypertriglyceridemia secondary to venlafaxine use in an older adult on dialysis -case report. BMC Health Serv Res. 2017 Apr 13;17(1):272. doi: 10.1186/s12913-017-2195-2. PubMed PMID: 28407764; PubMed Central PMCID: PMC5390401.
2: Kaufman MB, Pham T, Parameswaran L, Choy M. Prasugrel hypersensitivity with respiratory distress and rash. Am J Health Syst Pharm. 2016 Jul 15;73(14):1051-7. doi: 10.2146/ajhp150327. PubMed PMID: 27385702.
3: McKean J, Watts H, Mokszycki R. Breakthrough seizures after starting vilazodone for depression. Pharmacotherapy. 2015 Mar;35(3):e6-8. doi: 10.1002/phar.1549. PubMed PMID: 25809181.
4: Štuhec M. Excessive sweating induced by interaction between agomelatine and duloxetine hydrochloride: case report and review of the literature. Wien Klin Wochenschr. 2015 Sep;127(17-18):703-6. doi: 10.1007/s00508-014-0688-0. Epub 2015 Jan 10. Review. PubMed PMID: 25576334.
5: Ferreira PG, Costa S, Dias N, Ferreira AJ, Franco F. Simultaneous interstitial pneumonitis and cardiomyopathy induced by venlafaxine. J Bras Pneumol. 2014 May-Jun;40(3):313-8. English, Portuguese. PubMed PMID: 25029655; PubMed Central PMCID: PMC4109204.
6: Williams MF, Maloof JA 3rd. Resolution of clopidogrel-associated polyarthritis after conversion to prasugrel. Am J Health Syst Pharm. 2014 Jul 1;71(13):1097-100. doi: 10.2146/ajhp130518. PubMed PMID: 24939499.
7: Iuppa CA, Diefenderfer LA. Risperidone-induced Pisa syndrome in MS: resolution with lurasidone and recurrence with Chlorpromazine. Ann Pharmacother. 2013 Sep;47(9):1223-8. doi: 10.1177/1060028013503132. PubMed PMID: 24259741.
8: Angelo LJ, Lee KC. Dose-related paresthesias with venlafaxine. J Pharm Pract. 2013 Oct;26(5):514-7. doi: 10.1177/0897190013489573. Epub 2013 Jun 13. PubMed PMID: 23764565.
9: Kaufman KR, Podolsky D, Greenman D, Madraswala R. Antidepressant-selective gynecomastia. Ann Pharmacother. 2013 Jan;47(1):e6. doi: 10.1345/aph.1R491. Epub 2013 Jan 16. PubMed PMID: 23324513.
10: Ruggiero S, Rafaniello C, Bravaccio C, Grimaldi G, Granato R, Pascotto A, Sportiello L, Parretta E, Rinaldi B, Panei P, Rossi F, Capuano A. Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. J Child Adolesc Psychopharmacol. 2012 Dec;22(6):415-22. doi: 10.1089/cap.2012.0003. PubMed PMID: 23234585.
11: Nazer LH, Shankar G, Ali BA, Al-Najjar T. Fatal agranulocytosis associated with psychotropic medication use. Am J Health Syst Pharm. 2012 May 15;69(10):863-7. doi: 10.2146/ajhp110195. PubMed PMID: 22555081.
12: Kruithof MK, Bruins NA, van Roon EN. Coma after overdose with duloxetine. Ann Pharmacother. 2011 Jan;45(1):e5. doi: 10.1345/aph.1P432. Epub 2010 Dec 21. PubMed PMID: 21177420.
13: Steidl KE, Darko W, Probst LA, Noviasky JA, Nasser S. Rhabdomyolysis associated with phentermine. Am J Health Syst Pharm. 2010 Nov 15;67(22):1929-32. doi: 10.2146/ajhp090395. PubMed PMID: 21048209.
14: Prlesi L, Plakogiannis R. Angioedema after nonsteroidal antiinflammatory drug initiation in a patient stable on an angiotensin-converting-enzyme inhibitor. Am J Health Syst Pharm. 2010 Aug 15;67(16):1351-3. doi: 10.2146/ajhp090348. PubMed PMID: 20689124.
15: Charniot JC, Vignat N, Monsuez JJ, Kidouche R, Avramova B, Artigou JY, Albertini JP. Cardiogenic shock associated with reversible dilated cardiomyopathy during therapy with regular doses of venlafaxine. Am J Emerg Med. 2010 Feb;28(2):256.e1-5. doi: 10.1016/j.ajem.2009.05.010. PubMed PMID: 20159409.
16: Kelesidis T, Kelesidis I. Unexplained high fever in an elderly patient treated with clonidine, duloxetine, and atorvastatin. Clin Ther. 2009 Dec;31(12):2894-9. doi: 10.1016/j.clinthera.2009.12.008. PubMed PMID: 20110028.
17: Glance LE, Cumpston A, Kanate A, Remick SC. Bendamustine-associated hemolytic anemia. Ann Pharmacother. 2009 Nov;43(11):1903-6. doi: 10.1345/aph.1M329. Epub 2009 Oct 6. PubMed PMID: 19809007.
18: Giannikopoulos G, Zorzou MP, Stamoulis I, Panagi G, Sitaras P, Georgopoulos I, Hadjileontis C, Malakos I, Kyriazis J. Cinacalcet-induced leukocytoclastic vasculitis. Am J Kidney Dis. 2009 Aug;54(2):e5-8. doi: 10.1053/j.ajkd.2009.02.019. Epub 2009 Jun 28. PubMed PMID: 19560849.
19: Stevens DL. Duloxetine-associated tachycardia. Ann Pharmacother. 2008 Oct;42(10):1511-3. doi: 10.1345/aph.1L108. Epub 2008 Aug 26. PubMed PMID: 18728105.
20: Colucci VJ, Berry BD. Heart failure worsening and exacerbation after venlafaxine and duloxetine therapy. Ann Pharmacother. 2008 Jun;42(6):882-7. doi: 10.1345/aph.1L031. Epub 2008 Apr 29. PubMed PMID: 18445706.
